U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905131) titled 'A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer' on Oct. 23.
Brief Summary: The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.
Study Start Date: Jan. 15, 2027
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
DRUG: Navlimetostat
Investigational, small molecule anticancer agent being developed for the treatment of ...